Date: 2011-08-30
Type of information: Commercialisation agreement
Compound: Inspiration's hemophilia portfolio
Company: Ipsen (France) Inspiration Biopharmaceuticals (USA)
Therapeutic area: Hematological diseases - Genetic diseases - Rare diseases
Type agreement: commercialisation
Action mechanism:
Disease: hemophilia
Details: Ipsen and Inspiration Biopharmaceuticals have entered into a strategic partnership agreement, to create a European haemophilia commercial organization, to launch Inspiration’s haemophilia product portfolio in Europe. This partnership is designed to leverage the combined strengths of Ipsen’s well established European commercial infrastructure and medical network, with Inspiration’s expertise in the field of hemophilia. Inspiration and Ipsen will work together to hire and train a highly specialized commercial team to serve as the exclusive sales organization in Europe for all haemophilia drugs commercialized under the Inspiration brand. This commercial organization will take the form of a haemophilia business unit nested within Ipsen’s existing commercial organization.
Inspiration currently has two product candidates in pivotal clinical testing: IB1001, an intravenous recombinant factor IX (FIX) product being developed for the treatment and prevention of bleeding in individuals with haemophilia B, and OBI-1, an IV porcine recombinant factor VIII (FVIII) product being developed for the treatment of bleeding in individuals with acquired haemophilia A and individuals with congenital haemophilia A who have developed inhibitors against human FVIII. Inspiration anticipates filing a Marketing Authorization Application with the European Medicines Agency for IB1001 by the end of this year.
Financial terms: Under the terms of this commercial agreement, the haemophilia business unit will act as the exclusive commercial agent for all Inspiration products sold in the European Union, Russia and other European countries (in a total of 53 countries). Sales in the business unit will be booked by Inspiration. Ipsen will book all related sales and marketing expenses, rebill them to Inspiration and record them in Other Revenues. Additional financial terms of the agreement were not disclosed. In January 2010, Inspiration and Ipsen entered into a broad strategic partnership to develop and commercialize a portfolio of haemophilia products, which included Inspiration in-licensing OBI-1 from Ipsen, as well as Ipsen providing Inspiration with $259 million in milestone-based funding, to support the development of Inspiration’s two lead development programs.
Latest news:
